Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 171Docetaxel 164Paclitaxel 160Trastuzumab 152Capecitabine 130Tamoxifen 119Letrozole 105Epirubicin 93Doxorubicin 83Anastrozole 83exemestane 77Fulvestrant 75Carboplatin 64Fluorouracil 63Radiotherapy 61pertuzumab 59Gemcitabine 55Vinorelbine 43Goserelin 39eribulin 36130-nm albumin-bound paclitaxel 36palbociclib 32Bevacizumab 32ribociclib 30Zoledronic Acid 29Lapatinib 29Methotrexate 28Drug Therapy 28Chemotherapy, Adjuvant 28Ado-Trastuzumab Emtansine 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Epothilones × Breast × Clear all
NCT00785291 2022-10-10

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 3 Completed
799 enrolled 18 charts
Breast

Breast Neoplasms

NCT00080301 2020-11-02

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

R-Pharm

Phase 3 Completed
752 enrolled 22 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00082433 2020-11-02

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

R-Pharm

Phase 3 Completed
1,221 enrolled 18 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡